Deadline: 15 March 2025
The AIM-HI Accelerator Fund is proud to present the BRACE Award Venture Competition 2025 in collaboration with their partner organization, the Asian Fund for Cancer Research (AFCR)!
This competition is comprised of three parts: general information, a presentation summarizing a business plan, and a brief video delivered in easy-to-understand language for a general audience.
Funding Information
- An Investment Committee will conduct detailed due diligence research on the finalists to determine whether an investment will be made based on the technology platform merits, cancer patient impact, and potential for return on investment. The company that passes the due diligence process will receive up to $600,000 in investment from AIM-HI, AFCR and co-investors.
Eligibility Criteria
- Early-stage oncology companies worldwide seeking pre-seed, seed, and Series A investments are eligible to apply.
- The applying company must have technology ownership in place, and its technology should be able to address cancers prevalent in underserved populations.
Selection Criteria
- Their three-part Selection, Judging, and Investment Committees consist of world-class life sciences industry professionals, business leaders, and investors.
- All submitted applications will be reviewed and screened by their Selection Committee based on the quality of applications. Semi-finalists will be chosen around late April and invited to compete in front of a Judging Committee in June to select finalists who will be recognized and awarded honorariums and certificates.
For more information, visit AIM-HI Accelerator Fund.
